The Mercer brand is getting a new owner, and it will be a big deal.

The company’s parent company, Merck & Co., announced plans to sell its global health and wellness brand to a group led by billionaire Warren Buffett, who is investing $25 billion into the business.

Merck and its sister company, the pharmaceutical giant Pfizer, have long been in a fight with the government over how to treat HIV.

They argue that the government needs to use the drugs to prevent the virus spreading to people who are infected and treat people who have not yet contracted the disease.

But there is a big difference between treating HIV patients who are already infected and those who have just recently been infected, said Dr. Mark Litt, an infectious disease expert at Johns Hopkins University who has been tracking Merck’s progress with the FDA.

Litt said that as the price of the drugs has fallen, many of the same companies that are battling the government are also getting into the same business, and that there is no reason for the two sides to be fighting.

That is a problem, he said, because it creates a financial risk for the companies if Merck gets caught up in the government’s war on drugs.

Mercer is not the only drugmaker that has made moves into the health care business, though.

Pfizer and Merck are both pursuing similar ventures, but both have had to contend with government regulations.

Mercher was acquired by Pfizer in 2005 for $6.8 billion, and Pfizer has a controlling stake in the company.

The deal will see Merck take over a health care empire that was once a private enterprise that relied on a single pharmaceutical company for research and development.

It is the latest in a long line of acquisitions that have been led by private equity firms.

Merck and Berkshire Hathaway are both investing in drug companies.

Last month, the hedge fund billionaire Warren Buffet and his wife, Ann, invested $10 billion in Boston-based company Amgen.

Mercers drug, Sovaldi, has been in development for almost three years, but it was not approved for human use until December 2015.

That is when a new class of medicines called Cervarix was approved, and Merkeys drug, Nuvigil, also went on the market.

That class of drugs is used to treat severe viral infections.

Merkey has had a big success, but the drug has been heavily criticized for causing side effects such as fever and blood clots.

The FDA, which regulates the use of such drugs, has said that the drug may cause more serious side effects than others.

Merkeys new drug, Avantafil, is also in development.

The company is trying to develop a vaccine that will protect people against the virus that causes AIDS, and is trying in part to use Cervax to do so.

Avantafils development is not without controversy.

A report in The Wall Street Journal on Monday said that some experts are concerned about the potential for the vaccine to make people more vulnerable to the virus.

The study was done by a group of researchers at the University of Chicago and the Harvard School of Public Health.

Dr. David Scharf, a researcher at the Yale School of Medicine, said the vaccine would likely be safer than Cervay.

He said that it could help to prevent people from contracting the virus more quickly and to stop the virus from spreading from one person to another.

But critics have argued that the new vaccine may cause side effects that could make it less effective than other vaccines, including Cervix.

They have raised concerns that the vaccine could not protect against many of Avantavir’s side effects.

The vaccine could also have problems with side effects, including diarrhea, nausea and vomiting, as well as heart problems and even blindness, according to a study in The Journal of the American Medical Association.

In its announcement on Monday, Merkeying said it is working with regulators in the U.S. and the European Union to make sure that all the side effects are documented and that the company can provide adequate safeguards.

Mercker also said that Merck will take steps to ensure the safety of the vaccine for all those who are being tested for it.

It’s not clear when Avantacil will be available.

Pfizers said that there was no timeline for its launch, but Merck said it will take advantage of the fact that it was approved earlier in the year.

Mercury and Pfizers will be making a $6 billion investment in Avantaq, which is developing a vaccine to fight HIV.

The new company will also make money from the sale of Avastin, Mercy said.

Avastin is an antiviral drug that is also used to fight other types of cancers.